Literature DB >> 27052250

[Antihyperglycemic treatment guidelines for diabetes mellitus type 2].

Martin Clodi1,2, Heidemarie Abrahamian3, Heinz Drexel4, Peter Fasching5, Bernhard Föger6, Claudia Francesconi7, Friedrich Hoppichler8, Susanne Kaser9, Alexandra Kautzky-Willer10, Monika Lechleitner11, Bernhard Ludvik12, Rudolf Prager13, Elke Fröhlich-Reiterer14, Michael Roden15, Christoph Säly4, Guntram Schernthaner16, Harald Sourij17, Hermann Toplak17, Thomas C Wascher18, Raimund Weitgasser19.   

Abstract

Hyperglycemia significantly contributes to micro- and macrovascular complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals.

Entities:  

Keywords:  Diabetes mellitus Type 2; Glucose lowering; Therapy

Mesh：

Substances：

Year:  2016        PMID： 27052250     DOI： 10.1007/s00508-016-0991-z

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


  18 in total

1.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Authors:  Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

2.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

3.  Basal insulin and cardiovascular and other outcomes in dysglycemia.

Authors:  Hertzel C Gerstein; Jackie Bosch; Gilles R Dagenais; Rafael Díaz; Hyejung Jung; Aldo P Maggioni; Janice Pogue; Jeffrey Probstfield; Ambady Ramachandran; Matthew C Riddle; Lars E Rydén; Salim Yusuf
Journal:  N Engl J Med       Date:  2012-06-11       Impact factor: 91.245

4.  Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

5.  Glucose control and vascular complications in veterans with type 2 diabetes.

Authors:  William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang
Journal:  N Engl J Med       Date:  2008-12-17       Impact factor: 91.245

6.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

7.  The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

Authors:  Erland Erdmann; John A Dormandy; Bernard Charbonnel; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene
Journal:  J Am Coll Cardiol       Date:  2007-04-16       Impact factor: 24.094

8.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Authors:  Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel
Journal:  N Engl J Med       Date:  2009-06-07       Impact factor: 91.245
View more
  3 in total

Review 1.  Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition.

Authors:  Friedrich C Prischl; Christoph Wanner
Journal:  Kidney Int Rep       Date:  2018-04-22

2.  Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study.

Authors:  Helmut Brath; Heidemarie Abrahamian; Tvrtko Karuza; Roman Mihaljevic; Martin Pfohl
Journal:  Diabetes Ther       Date:  2019-01-17       Impact factor: 2.945

3.  Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012-2018.

Authors:  Clemens Engler; Marco Leo; Bernhard Pfeifer; Martin Juchum; Di Chen-Koenig; Karin Poelzl; Hans Schoenherr; David Vill; Juliana Oberdanner; Egon Eisendle; Klaus Middeldorf; Bernhard Heindl; Hannes Gaenzer; Gerald Bode; Karl Kirchmeyr; Guenther Ladner; Lisa Rieger; Ursula Koellensperger; Andrea Schwaiger; Florian Stoeckl; Guenther Zangerl; Monika Lechleitner; Irmgard Delmarko; Wilhelm Oberaigner; Clemens Rissbacher; Herbert Tilg; Christoph Ebenbichler
Journal:  BMJ Open Diabetes Res Care       Date:  2020-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.